BenevolentAI delists and merges with Osaka Holdings

BenevolentAI, a pioneer in AI-driven drug discovery with Cambridge facilities at Babraham Hall, is demerging from Euronext Amsterdam via a merger with Japanese-owned Osaka Holdings.

BenevolentAI Executive Chair, Kenneth Mulvany. Image courtesy – BenevolentAI.

The move will transition the business to a private company structure. BenevolentAI says the decision will simplify the share structure and related instruments and thereby cut the current complexity and administrative overheads seen as holding back the growth of the business.

On the merger, scheduled for completion on March 12, all BenevolentAI’s assets, liabilities, rights and obligations will transfers to Osaka Holdings under universal title of succession.

Kenneth Mulvany, Executive Chair of BenevolentAI, said: “After careful review and, in particular, consideration of the costs attributable to the company maintaining its listing on Euronext, the Board has unanimously concluded that the proposed delisting is in the best interests of BenevolentAI and its shareholders.

“The Board is firmly of the view that the company must prioritise investment that accelerates its innovation cycle and enhances product development. The proposed delisting is a crucial component of the company’s capital allocation and fiscal efficiency.”

BenevolentAI serves patients by leveraging its proprietary and validated Benevolent Platform™ that integrates AI and science to uncover new biology and predict novel targets for complex diseases. Its advanced AI tools and scientific expertise have nudged BenevolentAI to the forefront of reshaping the future of drug discovery and delivering innovative medicines.

Newsdesk

news@businessweekly.co.uk